FSIP1促进乳腺癌细胞迁移和侵袭并导致患者不良预后

doi:10.11904/j.issn.1002-3070.2022.03.007

Abstract

Abstract: Objective The aims of this study were to investigate the effect of FSIP1 expression in breast cancer tissues on the migration and invasion ability of breast cancer cells,and its relationship with the prognosis of breast cancer patients,so as to provide certain theoretical reference for the diagnosis and treatment of breast cancer. Methods The breast tissue samples and case data of 404 breast cancer patients diagnosed in Harbin Medical University Cancer Hospital from January 2004 to December 2018 were collected.The collected data of breast cancer patients were retrospectively analyzed and the survival curve was plotted by Kaplan-Meier method.Immunohistochemistry was used to analyze the expression of FSIP1 in breast cancer and adjacent tissues,and breast cancer MCF-7,MDA-MB-231,MDA-MB-435,SK-BR-3,T-47D and HMECs(MCF-10A)cell lines were cultured.The FSIP1 gene in breast cancer MDA-MB-231 and SK-BR-3 cell lines was knocked out using CRISPR/CAS9 technology and detected by Western blot.The effect of FSIP1 gene knockout on migration and invasion abilities of breast cancer cells was evaluated through cell migration and invasion assays. Results Compared with HMECs(MCF-10A),the expression of FSIP1 in breast cancer MCF-7,MDA-MB-231,MDA-MB-435,SK-BR-3,and T-47D cell lines was significantly increased(P＜0.01).Compared with adjacent breast tissues,the expression of FSIP1 in breast cancer tissues was significantly increased(P＜0.01).Survival analysis showed that the overall survival of breast cancer patients with the high expression of FSIP1 was significantly shortened(P＜0.01).The expression of FSIP1 was correlated with the clinical stage of breast cancer(P=0.0061)and the expression of cell proliferation marker-Ki-67(P=0.0067).The results of migration and invasion experiments showed that after knocking out the FSIP1 gene,the migration and invasion capabilities of breast cancer MDA-MB-231 and SK-BR-3 cells were significantly reduced(P＜0.01). Conclusion The high expression of FSIP1 in breast cancer cells can enhance their migration and invasion capabilities,and is correlated with the poor prognosis of patients.

Key words: Fibrous sheath interacting protein 1, Breast cancer, Migration, Invasion

CLC Number:

R737.9

HE Weidan, LI Zhigao. FSIP1 promotes migration and invasion of breast cancer cells and leads to poor prognosis of patients[J]. Journal of Practical Oncology, 2022, 36(3): 233-238.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.03.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I3/233

References

1 Koual M,Tomkiewicz C,Cano-Sancho G,et al.Environmental chemicals,breast cancer progression and drug resistance[J].Environ Health,2020,19(1):117-122.
2 Andersson Y,Bergkvist L,Frisell J,et al.Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes[J].Breast Cancer Res Treat,2018,171(2):359-369.
3 Chun KH,Park JH,Fan S.Predicting and overcoming chemotherapeutic resistance in breast cancer[J].Adv Exp Med Biol,2017,1026:59-104.
4 靳团,张清媛.乳腺癌脑转移的信号通路和分子机制的研究进展[J].实用肿瘤学杂志,2017,31(5):468-471.
5 Feng Y,Wu M,Li S,et al.The epigenetically downregulated factor CYGB suppresses breast cancer through inhibition of glucose metabolism[J].J Exp Clin Cancer Res,2018,37(1):313.
6 余科达,韦光楠.70基因检测可作为制定早期乳腺癌治疗方案的辅助手段[J].循证医学,2019,19(3):142-144.
7 Steger G,Lüftner D,Stger H,et al.Management of HER2-positive early breast cancer[J].Breast Care(Basel),2018,13(6):453-455.
8 Liu T,Zhang H,Sun L,et al.FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness[J].Proc Natl Acad Sci U S A,2017,114(29):7683-7688.
9 Zhang H,Luo M,Jin Z,et al.Expression and clinicopathological significance of FSIP1 in breast cancer[J].Oncotarget,2015,6(12):10658-10666.
10 Bommer GT,Gerin I,Feng Y,et al.p53-mediated activation of miRNA34 candidate tumor-suppressor genes[J].Curr Biol,2007,17(15):1298-1307.
11 Cardoso F,Senkus E,Costa A,et al.4th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 4)+[J].Ann Oncol,2018,29(8):1634-1657.
12 Li W,Zheng X,Ren L,et al.Eipgenetic hypomethylation and upregulation of GD3s in triple negative breast cancer[J].Ann Transl Med,2019,7(23):723.
13 Grizzi G,Ghidini M,Botticelli A,et al.Strategies for increasing the effectiveness of aromatase inhibitors in locally advanced breast cancer:An evidence-based review on current options[J].Cancer Manag Res,2020,12:675-686.
14 Cappell KM,Sinnott R,Taus P,et al.Multiple cancer testis antigens function to support tumor cell mitotic fidelity[J].Mol Cell Biol,2012,32(20):4131-4140.
15 Salem AF,Whitaker-Menezes D,Howell A,et al.Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance[J].Cell Cycle,2012,11(22):4174-4180.
16 Liu C,Sun L,Yang J,et al.FSIP1 regulates autophagy in breast cancer[J].Proc Natl Acad Sci USA,2018,115(51):13075-13080.
17 Yousefnia S,Seyed FF,Seyed FS,et al.Mechanistic pathways of malignancy in breast cancer stem cells[J].Front Oncol,2020,10:452.
18 Abolghasemi M,Tehrani SS,Yousefi T,et al.MicroRNAs in breast cancer:roles,functions,and mechanism of actions[J].J Cell Physiol,2020,235(6):5008-5029.
19 Guo S,Deng CX.Effect of stromal cells in tumor microenvironment on metastasis initiation[J].Int J Biol Sci,2018,14(14):2083-2093.
20 Izawa Y,Kashii-Magaribuchi K,Yoshida K,et al.Stem-like human breast cancer cells initiate vasculogenic mimicry on matrigel[J].Acta Histochem Cytochem,2018,51(6):173-183.

[1]	YANG Zihan, XU Shouping, PANG Da. Characteristics of breast cancer metastases to outer triangle tissue and its influencing factors [J]. Journal of Practical Oncology, 2022, 36(3): 226-232.
[2]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[3]	YANG Shuya, LIU Wenhui, LUO Naixiang. Research status and application prospect of UCA1 in breast cancer [J]. Journal of Practical Oncology, 2022, 36(3): 263-267.
[4]	LIU Wanying, PANG Da. Research progress on the mechanism of metastasis in invasive micropapillary carcinoma of the breast [J]. Journal of Practical Oncology, 2022, 36(3): 268-272.
[5]	SUN Yuanyuan, ZHANG Ningzhi, CAO Mengru. The mechanism and treatment progress of breast cancer lung metastasis [J]. Journal of Practical Oncology, 2022, 36(2): 173-177.
[6]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.
[7]	CHEN He, WANG Qiucheng, CHENG Wen. The application progress of automatic breast ultrasound diagnosis system in breast cancer [J]. Journal of Practical Oncology, 2022, 36(2): 193-196.
[8]	LI Weihua, ZHANG Guangfeng, MA Lili, HE Pin, WANG Wen, LI Dingfu. Construction of a breast cancer prognostic model based on metabolism-related genes in the TCGA database [J]. Journal of Practical Oncology, 2022, 36(1): 37-43.
[9]	WANG Yang, LI Guodong, TANG Qingchao, LIU Ming. Research progress of acidosis in colorectal malignant tumors [J]. Journal of Practical Oncology, 2022, 36(1): 74-78.
[10]	CAO Shiyu, JIANG Yongdong. The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer [J]. Journal of Practical Oncology, 2022, 36(1): 89-93.
[11]	LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis [J]. Journal of Practical Oncology, 2021, 35(6): 523-528.
[12]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[13]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[14]	ZHOU Tianhong, GU Xiuying, YAO Fang, SONG Shuming. Analysis for screening results of breast cancer in Urumqi from 2014 to 2018 [J]. Journal of Practical Oncology, 2021, 35(5): 391-395.
[15]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.

FSIP1 promotes migration and invasion of breast cancer cells and leads to poor prognosis of patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments